Skip to main content
NVDA-0.15%AAPL+0.03%MSFT+0.12%GOOGL+1.19%AMZN+0.11%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA-0.20%META-0.05%LLY+0.22%BRK-B-1.02%MU-0.28%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%EURUSD-0.70%USDJPY+0.70%USDMXN+0.58%NZDMXN+0.57%AUDDKK+0.56%AUDJPY+0.55%EURAUD-0.55%USDCHF+0.53%GBPUSD-0.53%EURZAR-0.50%EURCNH-0.50%EURHKD-0.47%USDDKK+0.46%EURSEK-0.43%EURSGD-0.41%GBPTRY+0.41%AUDCHF+0.39%EURNZD-0.38%GBPAUD-0.37%CADJPY+0.37%USDPLN+0.35%USDCAD+0.35%NZDJPY+0.35%EURCAD-0.34%NZDUSD-0.34%GBPZAR-0.34%GBPHKD+0.32%EURNOK-0.29%GBPMXN-0.28%AUDNOK+0.28%SGDJPY+0.26%GBPSGD-0.25%USDTRY+0.22%GBPCAD-0.19%EURCHF-0.19%CHFJPY+0.19%AUDCAD+0.18%CADCHF+0.18%AUDNZD+0.18%GBPNZD-0.18%NZDCHF+0.18%CHFSEK-0.17%EURGBP-0.17%USDNOK+0.17%GBPJPY+0.17%USDILS+0.16%AUDUSD-0.16%CHFSGD-0.16%AUDSGD+0.14%NOKJPY+0.13%EURPLN-0.10%EURCZK-0.07%PLNJPY-0.05%USDZAR-0.04%USDCOP-0.04%USDSGD+0.04%USDHKD+0.04%USDCNH-0.04%CHFNOK-0.03%USDSEK+0.02%NZDSGD+0.02%USDTHB+0.01%GBPCHF-0.01%EURJPY+0.01%NZDCAD-0.01%EURDKK0.00%HG1+1.81%XNGUSD+1.19%XAUUSD+1.10%GAUUSD+1.10%USOIL-1.04%XAGUSD+0.90%GAGUSD+0.89%XPTUSD+0.87%UKOIL-0.63%SUGAR0.00%COTTON0.00%W10.00%BTCUSD+0.93%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.73%ZECUSDT+5.51%DOGEUSD+20.65%XMRUSDT+1.05%LINKUSD+25.58%BCHUSDT+3.22%XLMUSD+0.48%UNIUSD-0.96%LTCUSD+17.89%SUIUSD+0.81%HBARUSDT-1.77%TONUSD+41.71%TAOUSDT+0.88%AAVEUSD-2.36%DOTUSDT-1.58%ICPUSDT-2.09%ONDOUSDT+0.12%WLDUSDT+0.14%ARBUSDT-0.80%JUPUSDT+0.30%INJUSDT+0.65%ATOMUSDT-1.06%STXUSDT-1.40%TIAUSDT-0.51%PYTHUSDT-3.01%FETUSDT+3.30%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+1.15%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT-0.02%POLUSDT+0.73%AXSUSDT+0.62%EOSUSDT+0.75%FARTCOINUSDT+2.14%DYDXUSDT+3.06%GALAUSDT+0.98%ORDIUSDT+2.26%RONINUSDT+1.89%NOTUSDT+1.92%NVDA-0.15%AAPL+0.03%MSFT+0.12%GOOGL+1.19%AMZN+0.11%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA-0.20%META-0.05%LLY+0.22%BRK-B-1.02%MU-0.28%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%EURUSD-0.70%USDJPY+0.70%USDMXN+0.58%NZDMXN+0.57%AUDDKK+0.56%AUDJPY+0.55%EURAUD-0.55%USDCHF+0.53%GBPUSD-0.53%EURZAR-0.50%EURCNH-0.50%EURHKD-0.47%USDDKK+0.46%EURSEK-0.43%EURSGD-0.41%GBPTRY+0.41%AUDCHF+0.39%EURNZD-0.38%GBPAUD-0.37%CADJPY+0.37%USDPLN+0.35%USDCAD+0.35%NZDJPY+0.35%EURCAD-0.34%NZDUSD-0.34%GBPZAR-0.34%GBPHKD+0.32%EURNOK-0.29%GBPMXN-0.28%AUDNOK+0.28%SGDJPY+0.26%GBPSGD-0.25%USDTRY+0.22%GBPCAD-0.19%EURCHF-0.19%CHFJPY+0.19%AUDCAD+0.18%CADCHF+0.18%AUDNZD+0.18%GBPNZD-0.18%NZDCHF+0.18%CHFSEK-0.17%EURGBP-0.17%USDNOK+0.17%GBPJPY+0.17%USDILS+0.16%AUDUSD-0.16%CHFSGD-0.16%AUDSGD+0.14%NOKJPY+0.13%EURPLN-0.10%EURCZK-0.07%PLNJPY-0.05%USDZAR-0.04%USDCOP-0.04%USDSGD+0.04%USDHKD+0.04%USDCNH-0.04%CHFNOK-0.03%USDSEK+0.02%NZDSGD+0.02%USDTHB+0.01%GBPCHF-0.01%EURJPY+0.01%NZDCAD-0.01%EURDKK0.00%HG1+1.81%XNGUSD+1.19%XAUUSD+1.10%GAUUSD+1.10%USOIL-1.04%XAGUSD+0.90%GAGUSD+0.89%XPTUSD+0.87%UKOIL-0.63%SUGAR0.00%COTTON0.00%W10.00%BTCUSD+0.93%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.73%ZECUSDT+5.51%DOGEUSD+20.65%XMRUSDT+1.05%LINKUSD+25.58%BCHUSDT+3.22%XLMUSD+0.48%UNIUSD-0.96%LTCUSD+17.89%SUIUSD+0.81%HBARUSDT-1.77%TONUSD+41.71%TAOUSDT+0.88%AAVEUSD-2.36%DOTUSDT-1.58%ICPUSDT-2.09%ONDOUSDT+0.12%WLDUSDT+0.14%ARBUSDT-0.80%JUPUSDT+0.30%INJUSDT+0.65%ATOMUSDT-1.06%STXUSDT-1.40%TIAUSDT-0.51%PYTHUSDT-3.01%FETUSDT+3.30%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+1.15%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT-0.02%POLUSDT+0.73%AXSUSDT+0.62%EOSUSDT+0.75%FARTCOINUSDT+2.14%DYDXUSDT+3.06%GALAUSDT+0.98%ORDIUSDT+2.26%RONINUSDT+1.89%NOTUSDT+1.92%
FT

First Tracks Biotherapeutics Inc (TRAX)

NASDAQ • Healthcare

$45.38
+$1.9 (+4.4%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$43.9
Day Range$43.27 - $46.08
Avg. Volume (3M)1.1M
Market Cap$1.6B
52 Week Range
$14.72$49.91
Next EarningsIn 15 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$83.8M
EPS (TTM)
-$2.39
ROA (TTM)
-68.97%
Current Ratio
10.2

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-18.4%Q3 2026-$0.95
Next

Nov 11

in 15 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -18.4%

First Tracks Biotherapeutics’ preliminary results for the second fiscal quarter of 2026, reported August 12, 2026, showed EPS of -$0.95 trailed the -$0.80 estimate by -$0.15 as the clinical-stage immunology developer continued to post losses. The company recorded GAAP operating income of roughly -$34.9 million and GAAP net income of about -$33.4 million, reflecting ongoing spending to advance its pipeline programs, including Rosnilimab, ANB033, and ANB101, through clinical development rather than commercial drug sales. Cash burn remained evident in liquidity generation as well, with negative operating cash flow of around -$31.9 million for the quarter.

Next report — what to expect

First Tracks Biotherapeutics Inc (TRAX) is scheduled to report on November 11, 2026. Consensus expects EPS of -$0.92. With limited history, TRAX has beaten EPS in 0 of 1 most recent quarters, so attention may center on whether results align with that EPS bar and any updates accompanying the release.

View full earnings history

About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc is a NASDAQ-listed Biotechnology company in the healthcare field that develops immunology-based treatments for autoimmune and inflammatory disorders. The company operates as a clinical-stage therapeutic developer rather than a commercial drug seller, with its work centered on discovering and advancing candidates through human testing.

Name
First Tracks Biotherapeutics Inc
CEO
Daniel R. Faga
Website
www.firsttracksbio.com
Industry
Healthcare
Employees
104

Today's Snapshot

AI-generated

The day ended with TRAX 4.4% higher at 45.38, while its sector was flat. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (967.6K)

606.9K

vs S&P 500 Today

Strong Outperformance

+3.68%

Updated: October 27, 2026 at 20:20 UTC

TRAX Headlines

Key biotech data and catalysts this week

October 11, 2026

3 min read
View All News

Peers & Related Assets

IMVTImmunovant, Inc.
$28.88+2.5%
ANABAnaptysBio, Inc.
$49.63+1.8%
MLTXMoonLake Immunotherapeutics
ODTXOdyssey Therapeutics, Inc.
ATTOAttovia Therapeutics, Inc.
CLYMClimb Bio, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.